An interferonopathy associated with a monoallelic variant in TRIM28

In this work, we describe the clinical and functional changes in a family with a novel type I interferonopathy phenotype which we suggest could be associated with a TRIM28 variant, presenting with chilblains, skin ulceration, lipodystrophy and calcinosis. TRIM28 has multiple roles in regulating human health and disease, which include DNA repair and anti-viral response. The latter includes negative regulation of IRF7, one of the master regulators of the interferon response. Whole exome sequencing and targeted panel sequencing was performed on DNA extracted from peripheral blood. Functional work included gene (qPCR), protein (WB) and cytokine (MSD and SIMOA) expression studies. Transfection studies of siRNA in control Human Dermal Fibroblast Cells (HDFCs) using RNAiMAX and of wild-type protein in patient HDFCs using FuGENE HD were also performed. Analysis of WES data according to a dominant model with incomplete penetrance revealed TRIM28 c.A623G; p.Y208C in the proband of Family A and his mildly affected mother. Gene expression studies revealed persistent elevation of interferon inducible proteins including increased gene as well as protein expression of IRF7. Cytokine measurements revealed a marked elevation of pro-inflammatory cytokines particularly IFNβ in affected individuals. A good clinical and functional response to treatment with baricitinib was documented, however the proband subsequently died of septic complications. TRIM28-siRNA transfection into control HDFCs resulted in changes in gene, protein and cytokine expression similar to those seen in the proband. Transfection of a wild-type pEGFP- TRIM28 plasmid into the proband’s HDFCs achieved partial rescue of the cellular phenotype. We describe a novel and severe interferonopathy potentially associated with an autosomal dominant TRIM28 variant with an incomplete penetrance disease model, presenting with skin ulceration, calcinosis, high interferon scores, and upregulation of IRF7. Pathogenicity was supported by TRIM28 gene silencing in healthy HDFCs. Polymorphisms in other genes such as ITGAM could modulate penetrance and expressivity.

Authors

Institutions

Publication Details

Journal
Pediatric Rheumatology
Published
2026-07-25
DOI
https://doi.org/10.1186/s12969-026-01248-x
Primary Topic
interferon and immune responses
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

An interferonopathy associated with a monoallelic variant in TRIM28

Charalampia Papadopoulou, Darragh Duffy, Ebun Omoyinmi, Luís Seabra et al.
Pediatric Rheumatology
interferon and immune responses
article

An interferonopathy associated with a monoallelic variant in TRIM28

Charalampia Papadopoulou, Darragh Duffy, Ebun Omoyinmi, Luís Seabra, Josiana Gomes, Vincent Bondet, Sónia Gomes, Glenn Anderson, Paul Brogan, Fionnuala McMorrow, Ying Hong, Florence Adams, Gillian Rice
article en

Abstract

In this work, we describe the clinical and functional changes in a family with a novel type I interferonopathy phenotype which we suggest could be associated with a TRIM28 variant, presenting with chilblains, skin ulceration, lipodystrophy and calcinosis. TRIM28 has multiple roles in regulating human health and disease, which include DNA repair and anti-viral response. The latter includes negative regulation of IRF7, one of the master regulators of the interferon response. Whole exome sequencing and targeted panel sequencing was performed on DNA extracted from peripheral blood. Functional work included gene (qPCR), protein (WB) and cytokine (MSD and SIMOA) expression studies. Transfection studies of siRNA in control Human Dermal Fibroblast Cells (HDFCs) using RNAiMAX and of wild-type protein in patient HDFCs using FuGENE HD were also performed. Analysis of WES data according to a dominant model with incomplete penetrance revealed TRIM28 c.A623G; p.Y208C in the proband of Family A and his mildly affected mother. Gene expression studies revealed persistent elevation of interferon inducible proteins including increased gene as well as protein expression of IRF7. Cytokine measurements revealed a marked elevation of pro-inflammatory cytokines particularly IFNβ in affected individuals. A good clinical and functional response to treatment with baricitinib was documented, however the proband subsequently died of septic complications. TRIM28-siRNA transfection into control HDFCs resulted in changes in gene, protein and cytokine expression similar to those seen in the proband. Transfection of a wild-type pEGFP- TRIM28 plasmid into the proband’s HDFCs achieved partial rescue of the cellular phenotype. We describe a novel and severe interferonopathy potentially associated with an autosomal dominant TRIM28 variant with an incomplete penetrance disease model, presenting with skin ulceration, calcinosis, high interferon scores, and upregulation of IRF7. Pathogenicity was supported by TRIM28 gene silencing in healthy HDFCs. Polymorphisms in other genes such as ITGAM could modulate penetrance and expressivity.

Pediatric Rheumatology
Inserm (FR), Université Paris Cité (FR), Manchester Academic Health Science Centre (GB), Great Ormond Street Hospital for Children NHS Foundation Trust (GB), Instituto Português de Malacologia (PT), Institut des Maladies Génétiques Imagine (FR), Instituto Português de Reumatologia, University College London (GB), University of Bath (GB)
National Institute for Health and Care Research
Good health and well-being
Openalex Percentile: Top 14%
interferon and immune responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.